Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan + pembrolizumab in HER2+ breast cancer and HER2+ NSCLC
NCT04042701Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan in breast cancer and non-small cell lung cancer (NSCLC) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 6 weeks and Objective Response Rate at 30 months. Started Feb 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04042701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042701.